Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
RESEARCH TOOLSreports
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-1.56Last Year’s EPS
-2.03Same Quarter Last Year
Strong Buy
Based on 16 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 13, 2025
|% Change Since: 2.21%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Positive
The earnings call reflected strong revenue growth and successful international expansion, alongside notable advancements in clinical programs. However, significant net losses and high operating expenses present financial challenges. The positive highlights slightly outweigh the concerns, indicating a cautiously optimistic outlook.Company Guidance
During the Ultragenyx Fourth Quarter and Full Year 2024 Financial Results Conference Call, the company reported impressive metrics and provided guidance for 2025. Ultragenyx announced a 2024 total revenue of $560 million, marking a 29% growth over the previous year. CRYSVITA contributed $410 million, DOJOLVI $88 million, EVKEEZA $32 million, and MEPSEVII $30 million to the total revenue. Operating expenses for 2024 reached $1.1 billion, resulting in a net loss of $569 million. Looking ahead to 2025, Ultragenyx anticipates total revenue between $640 million and $670 million, representing a growth range of 14% to 20% over 2024. Specifically, CRYSVITA revenue is expected to reach between $460 million and $480 million, and DOJOLVI revenue is projected between $90 million and $100 million. The company aims for full-year GAAP profitability by 2027 and continues to prioritize expense management while advancing its clinical pipeline and preparing for potential product launches.Exceeding Revenue Expectations
Ultragenyx reported a total revenue of $560 million for 2024, representing a 29% growth over 2023. They exceeded their increased guidance for total revenue, surpassing the upper end of the range.
International Expansion Success
Ultragenyx successfully launched EVKEEZA in Europe, Canada, and Japan, and expanded access in Latin America, Canada, and Turkey. This contributed to a 78% growth in CRYSVITA sales in Latin America and Turkey over 2023.
Clinical Program Advancements
Ultragenyx advanced 6 late-stage programs, including the filing of their first BLA for Sanfilippo syndrome and expected Phase 3 data on UX143 for osteogenesis imperfecta.
Strong Product Performance
CRYSVITA contributed $410 million in revenue, with DOJOLVI contributing $88 million, each showing significant growth over the previous year.
---
RARE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RARE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 13, 2025 | $43.52 | $42.49 | -2.37% |
| Nov 05, 2024 | $52.18 | $50.52 | -3.18% |
| Aug 01, 2024 | $44.15 | $50.47 | +14.31% |
| May 02, 2024 | $43.20 | $42.75 | -1.04% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Ultragenyx Pharmaceutical (RARE) report earnings?
Ultragenyx Pharmaceutical (RARE) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Ultragenyx Pharmaceutical (RARE) earnings time?
Ultragenyx Pharmaceutical (RARE) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RARE EPS forecast?
RARE EPS forecast for the fiscal quarter 2025 (Q1) is -1.56.
---